Glynis R. Ablon, M.D., spoke at the 18th annual South Beach Symposium in Miami about why microneedling with radiofrequency is an effective way to combat signs of aging skin. According to Dr. Ablon, benefits include minimal downtime and risk versus other options.
Cheryl Guttman Krader, BS, Pharm
Read more on the variety of new treatment options for acne, with even more awaiting approval.
Read insights from James Q. Del Rosso, D.O., as he discusses antibiotic resistance, isotretinoin relapse, and laboratory monitoring for patients on isotretinoin and spironolactone.
Published results from two 12-week, vehicle-controlled phase 3 studies show that a novel topical foam formulation of minocycline 1.5% may be effective in reducing inflammatory lesions.
James J. Leyden, M.D., has four decades of experience prescribing isotretinoin for the treatment of severe acne both in clinical practice and clinical research. Read his conclusions about dosing and use of the oral retinoid in this article.
Rhinophyma is a disfiguring condition with deleterious psychosocial and functional consequences, and its pathogenesis remains unclear. Deborah S. Sarnoff, M.D., offers insight on its etiology, and treatment options in this article.
A study showing differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders may be helpful to dermatologists as they consider treatment for patients with moderate-to-severe psoriasis, according to the investigators.
Switching patients with moderate-to-severe plaque psoriasis from one biologic to another is a multifactorial decision and may depend on safety, efficacy or dosing intervals. Ron Vender, M.D., offers insight into how to switch appropriately.
Topical ivermectin cream, 1% (Soolantra, Galderma) represents an advance in treatment for rosacea, offering superior efficacy and tolerability compared with previously available therapies, says Jeffrey S. Fromowitz, M.D., who spoke at the Orlando Dermatology Aesthetic & Clinical Conference.
Collective results from the SAKURA phase 3 clinical trial program investigating daxibotulinumtoxinA for injection for the treatment of moderate-to-severe glabellar lines show that the neuromodulator provides generally safe and long-lasting results.